BOTHELL, Wash.--(BUSINESS WIRE)--
Seattle Genetics, Inc. (SGEN) today announced the initiation of a phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with bendamustine for patients with Hodgkin lymphoma (HL) after first relapse. The multi-phase study is divided into two cohorts to determine the recommended dosing level and tolerability of combination use and to assess the complete remission rate associated with ADCETRIS in combination with bendamustine. Seattle Genetics is the leader in the field of antibody-drug conjugates (ADCs) and ADCETRIS is an ADC directed to CD30, a defining marker of classical HL. ADCETRIS is not approved for salvage HL patients who are deemed eligible for autologous stem cell transplant (ASCT).
One of the key goals of our broad ADCETRIS clinical development program is to evaluate its use in earlier lines of HL therapy. This trial will assess the ability of ADCETRIS in combination with bendamustine to induce durable complete remissions in second-line treatment of HL patients prior to transplant, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. In this treatment setting, single-agent bendamustine has been shown to induce a high rate of remissions with limited durability. Data from an investigator-sponsored trial with single-agent ADCETRIS demonstrated encouraging activity and tolerability in this setting. This trial is designed to determine if the combination can result in durable complete remissions, potentially increasing the number of patients eligible to receive a transplant.
This phase 1/2 single-arm, open-label clinical trial will evaluate the efficacy and tolerability of ADCETRIS in combination with bendamustine in HL patients after first relapse. Patients will be eligible to receive up to six cycles of ADCETRIS in combination with bendamustine followed by additional single-agent ADCETRIS for up to a total of 16 cycles. As a part of the trial design, after patients receive ADCETRIS plus bendamustine combination therapy, they have the option to pause therapy to receive an ASCT and then resume treatment with single-agent ADCETRIS as consolidation. Bendamustine is an alkylating agent used in the treatment of chronic lymphocytic leukemias and lymphomas. The primary endpoint of the phase 1 cohort is to determine the recommended dosing level of bendamustine in combination with ADCETRIS as well as the safety and tolerability of the combination. The primary endpoint of the phase 2 cohort is to assess the complete remission rate. Key secondary endpoints include best response, duration of response and progression-free survival. The study is expected to enroll up to 50 patients at multiple centers in the United States.
At the 54th American Society of Hematology (ASH) Annual Meeting and Exposition held December 8-11, 2012 in Atlanta, GA, encouraging data were presented from an abstract titled Brentuximab Vedotin as a First Line Salvage Therapy in Relapsed/Refractory HL (Abstract #3699). The investigator-sponsored trial was conducted to evaluate ADCETRIS as a salvage therapy for HL. Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with chemotherapy regimens or a combination of chemotherapy with or without consolidative radiation treatment.
Of the 14 evaluable patients, 12 patients (85.7 percent) had an objective response rate, including seven (50 percent) complete remissions and five (35.7 percent) partial remissions. The most common Grade 1 or 2 adverse events were peripheral sensory neuropathy (42.9 percent), acneiform rash (35.7 percent), AST elevation (28.6 percent) and fatigue (28.6 percent). Grade 3 adverse events were rash acneiform (7.1 percent) and urinary tract infection (7.1 percent), and there were no Grade 4 adverse events. The abstract can be found at http://www.hematology.org.
More information about the phase 1/2 trial of ADCETRIS in combination with bendamustine, including enrolling centers, is available by visiting http://www.clinicaltrials.gov.
About ADCETRIS
ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.
ADCETRIS was granted accelerated approval by the FDA in August 2011 and approval with conditions by Health Canada in February 2013 for two indications: (1) the treatment of patients with HL after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS.
Read more from the original source:
Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with ...
- ACT - Stem Cell Trial for AMD and Stargardt - Phase 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Excerpt from: "The Urban Wire" Internet Radio Podcast: FDA Oks embryonic stem cell trials for humans [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Advanced Cell Technology (ACT) AMD stem cell clinical phase [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Stem Cells Retina and cornea regeneration ACT Dr lanza - Advanced Cell Technology [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Spinal Patient Receives Stem Cells in First Experimental Treatment [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bloomberg: Geron, StemCells Rise 4% [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bringing Stem Cell Cures to the Clinic: UC Davis GMP Facility [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Researchers in California Show Results for Spinal Cord Injuries Using Embryonic Stem Cells [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bill Caldwell, Chairman [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT edmund vision stem cells program Advanced Cell Technology [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Texans for Stem Cell Research Learn for Life: KXAN Coverage Aired August 16th, 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT - Dr Lanza - Hermangioblast program - Advanced cell technology [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Anticipating the Next Decade of the Genome - Francis Collins, Director of NIH [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- New Epilepsy Treatment Under Study For Seizures - Part 1 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Thank You For Trevor Raborn [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- CBLI Breaking News [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem cell medical breakthrough? [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- NIST Colloquium Series: Next Generation Neural Implants [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Alan Lewis: Embryonic Stem Cell Therapies for diabetes [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2011 Predictions for Hair Transplant Developments | Arocha Hair Restoration [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Healthbeat - Stem Cell Research [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Living With ALS [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Revolutionary New Potential Treatment for Glioblastoma... [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Lyme Disease: Challenges and Innovations [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2010: Cord blood saving lives [CNN: 5-30-2011] [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Biotechnology, Diagnostics, and Genomics: Panel Discussion [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Pharmacogenomics [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Brickheads - Osteobots Practice Skit.mpg [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A veteran lives with ALS [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Healthy Body = Functional Body. Hollywood Look Side Effect: Healthy Function [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 2009 Flu Summit: Opening Remarks [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Cord Blood Breakthrough [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- SENS5 - Leucocyte transfusions as a novel immunotherapy for cancer patients [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Lymphoma Drug SGN-35 - The Nebraska Medical Center [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- ACell Hair Restoration with Dr. Gary Hitzig and Dr. Amiya Prasad - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Hans Keirstead: Developing therapies based on embryonic stem cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- NJN News Healthwatch Report - Cornea Treatment Study - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- HIV/AIDS may be prevented by new lubricant - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- MFIII Switzerland PE Sheep Placenta Glandular therapy Study - Client Interviews - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- Love Diabetes: BCG and Noncompliant Patients - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Dr. Alimorad Farshchian statement on embryonic stem cells - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- StemCellTV Daily Report-October 29, 2011 - Video [Last Updated On: October 30th, 2011] [Originally Added On: October 30th, 2011]
- Stephen McKenna MD - 8 - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- ALS Stem Cell Trial at Emory - Video [Last Updated On: November 22nd, 2011] [Originally Added On: November 22nd, 2011]
- Target Product Profile: Ellen Feigal - 2011 CIRM Grantee Meeting - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- Monoclonal Antibodies: Stanford Academia-Industry Collaboration - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- Parkinson's Disease Guidelines (Part 2) - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Macular Degeneration Drugs - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- BrainStorm Cell Therapeutics (OTCBB:BCLI) Has Potentially Developed A Treatment For ALS [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Stemedica Cell Technologies - Documentary - Video [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- (GMCR, STEM, DSCO) CRWENewswire.com Stocks In Action - Video [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Stem Cells Regrow Healthy Heart Muscle In Heart Attack Patients [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer Trial With I-124-CLR1404 (Light) Cancer ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress and New Initiatives [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Novelos Therapeutics and Academic Collaborators Have Three Abstracts Accepted for Presentation at 2012 AACR Annual ... [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 [Last Updated On: March 6th, 2012] [Originally Added On: March 6th, 2012]
- Will StemCells Walk The Talk? [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Internationally Recognized Leukemia Physician and Researcher to Lead Sylvester Comprehensive Cancer Center [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Criminal investigation after patient dies at office of doctor linked to stem cell [Last Updated On: March 9th, 2012] [Originally Added On: March 9th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Brain Cancer Trial with I-124-CLR1404 (LIGHT) Cancer ... [Last Updated On: March 15th, 2012] [Originally Added On: March 15th, 2012]
- Vitro Biopharma Receives Approval for Presentation to the International Society for Cellular Therapy [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Looking for Innovative Small-Cap Biotech Companies: George Zavoico [Last Updated On: March 26th, 2012] [Originally Added On: March 26th, 2012]
- Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of ... [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- Gentium Reports Fourth Quarter and Year End 2011 Financial Results [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- Basketball’s influence on stem cell treatments in sports medicine [Last Updated On: March 30th, 2012] [Originally Added On: March 30th, 2012]
- Cardium Announces U.S. Market Introduction of Excellagen™ [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult ... [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile ... [Last Updated On: April 1st, 2012] [Originally Added On: April 1st, 2012]
- SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC [Last Updated On: April 19th, 2012] [Originally Added On: April 19th, 2012]
- Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem's ERC Technology and Joins Advisory Board [Last Updated On: April 26th, 2012] [Originally Added On: April 26th, 2012]